The 17th edition of the International Congress on Targeted Anticancer Therapies (TAT) took place in Paris, 25-27 February 2019.
In the TAT 2019 programme, major updates and innovation in the field of cancer treatment using exciting novel targeted agents and immunotherapy were presented along with new points to consider, including the role of liquid biopsies as alternative to conventional tissue biopsies. The issue of combination in the use of immuno-oncology agents was largely discussed as well as new immuno-oncology methodological approaches. In addition to the usual congress sessions, Workshops at lunch time and “Meet the expert” sessions were planned to allow interactivity among the participants
TAT is the place of early phase clinical trials with new agents aiming at specific targets that may help patient selection.
Attending TAT 2019 fostered:
- Learning about new methodologies for a biomarker-selected patient population for early drug development including agnostic approaches
- Discovery of emerging therapeutic strategies based on new targets or pathways
- Continuing education in cancer immunotherapy rationale, potential combinations and the methodological challenge of evaluation
- Interaction and networking in workshop and “Meet the expert”-sessions
ESMO-MORA: The TAT 2019 programme has been accredited with 18 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.